ArticleFuture oncology (London, England)2026
Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.
Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimTo assess healthcare resource utilization (HRU) and costs among patients with metastatic pancreatic cancer (mPC). PATIENTS AND
methodsAdult US patients with an mPC diagnosis based on index date 1 January 2020-31 December 2022 were identified in the Merative MarketScan database. All-cause healthcare visits and costs (USD) were estimated per-person-per-month (PPPM) for 1 year post-index period. First-line (1L) treatments (≤90 days post-index) were categorized as FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin)-based, gemcitabine+paclitaxel-based, other, or none.
resultsClaims from 2318 patients with mPC were included: 68.6% (1589/2318) with commercial and 31.4% (729/2318) with Medicare. Mean total costs PPPM were $34,215 with commercial and $15,158 with Medicare. A total of 25.7% (409/1589) of commercially insured patients and 43.2% (315/729) of Medicare-insured patients did not receive 1L treatment. Median (interquartile range) cumulative length of stay was 0.8 days (0.1-2.4) with commercial insurance and 0.7 days (0.0-2.4) with Medicare. All-cause PPPM costs were higher for patients without 1L treatment than with 1L treatment in both insurance types, primarily driven by inpatient and outpatient visits.
conclusionsPatients with mPC experienced high economic burden, mostly attributable to inpatient and outpatient costs. The high rate of patients with mPC not receiving 1L treatment merits further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.